Drug research

sparsentan

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as RE-021

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyNCT03762850	TVTX	Phase 3	Active not recruiting	2023-08-07Actual
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)NCT03493685	TVTX	Phase 3	Completed	2023-03-20Actual

TVTXActive not recruitingPrimary completion: 2023-08-07 · Actual

Trial details

TVTXCompletedPrimary completion: 2023-03-20 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.